Prophylactic role of tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature

Table 2 Characteristics of study population

Characteristics	All patients (n = 104)	No COVID-19 infection (n = 91)	COVID-19 breakthrough infection (n = 13)	P value
Median age (IQR), year	50 (41-59)	50 (41-59)	50 (44-59)	0.48
Gender, n (%)				0.33
Female	45 (43.3)	41 (45.1)	4 (30.8)
Male	59 (56.7)	50 (54.9)	9 (69.2)
Race, n (%)				0.65
Black	51 (49.0)	44 (48.4)	7 (53.8)
White	49 (47.1)	44 (48.4)	5 (38.5)
Hispanic	3 (2.9)	2 (2.2)	1 (7.7)
Asian/Pacific Islander	1 (1.0)	1 (1.1)	0
Comorbidities, n (%)
Hypertension	100 (96.1)	87 (85.6)	13 (100)	0.44
Diabetes	49 (47.1)	39 (42.9)	10 (76.9)	0.21
COPD	4 (3.8)	3 (3.3)	1 (7.7)	0.44
Asthma	4 (3.8)	4 (4.4)	0	0.44
Current smoker	5 (4.8)	5 (5.5)	0	0.39
Coronary artery disease	10 (9.6)	10 (11.0)	0	0.21
Prior kidney transplant, n (%)	11 (10.6)	11 (12.1)	0	0.18
COVID-19 vaccine dose, n (%)				0.6
0	3 (2.9)	3 (3.3)	0
1	6 (5.8)	5 (5.5)	1 (7.7)
2	41 (39.4)	38 (41.8)	3 (23.1)
3	38 (36.5)	31 (34.1)	7 (53.8)
4	16 (15.4)	14 (15.4)	2 (15.4)
Donor type, n (%)				0.45
Deceased	83 (79.8)	71 (78.0)	12 (92.3)
Living	21 (20.2)	20 (22.0)	1 (7.7)
KDPI (%), n (%)				0.27
0-20	24 (29.3)	22 (31.4)	2 (16.7)
21-34	14 (17.1)	13 (18.6)	1 (8.3)
35-85	44 (53.7)	35 (50.0)	9 (75.0)
cPRA (%), n (%)				0.02
0	36 (34.6)	32 (35.2)	4 (30.8)
1-20	19 (18.3)	18 (19.8)	1 (7.7)
21-79	26 (25.0)	18 (19.8)	8 (61.5)
80-97	13 (12.5)	13 (14.3)	0
98-100	10 (9.6)	10 (11.0)	0
ABDR Ag mismatch, n (%)				0.15
0	7 (6.7)	4 (4.4)	3 (23.1)
1	3 (2.9)	3 (3.3)	0
2	6 (5.8)	6 (6.6)	0
3	17 (16.3)	16 (17.6)	1 (7.7)
4	28 (26.9)	25 (27.5)	3 (23.1)
5	27 (26.0)	22 (24.2)	5 (38.5)
6	16 (15.4)	15 (16.5)	1 (7.7)
Delayed graft function, n (%)	17 (16.3)	15 (16.5)	2 (15.4)	0.92
Induction immunosuppression, n (%)	102 (98.1)	89 (97.8)	13 (100)	0.59
Alemtuzumab	2 (1.9)	2 (2.2)	0
Basiliximab
Maintenance immunosuppression, n (%)				1
Tacrolimus	104 (100.0)	91 (100.0)	13 (100.0)
Mycophenolate	104 (100.0)	91 (100.0)	13 (100.0)
Prednisone	96 (92.3)	84 (92.3)	12 (92.31)

COVID-19: Coronavirus disease 2019; COPD: Chronic obstructive pulmonary disease; KDPI: Kidney donor profile index; cPRA: Calculated panel reactive antibody; Ag: Antigen; ABDR: Australian Breast Device Registry.